A Phase 3 interventional study of TEV-48125 and TEV-48125 in Migraine, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-17.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing fremanezumab in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. fremanezumab · Migraine Disorders.
Among the 21 studies testing fremanezumab in Migraine Disorders, this one is the 15th largest by enrollment, is one of 4 that started in 2017, is one of 9 in phase 3, and was the 6th registered.
1,659 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →1 of the 21 studies testing fremanezumab in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
fremanezumab: first FDA approval 2018 (AJOVY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2014; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 80 across 1,270 interventional studies indexed under Migraine Disorders.
Median enrollment 292 across the 21 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 6 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing fremanezumab in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653516Insel Gruppe AG, University Hospital BernCalcitonin Gene-related Peptide Antibody in Acute Mountain Sickness | 2027-07-31 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing fremanezumab in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly \[except for a loading dose of 675 mg in subjects with CM\]).
Drug: TEV-48125
TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
Drug: TEV-48125
TEV-48125 will be administered subcutaneously once every 4 weeks.
TEV-48125 will be administered subcutaneously once every 12 weeks.
Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE)
* TEAEs are defined as the AEs that started after trial investigational medicinal product (IMP) treatment. Multiple occurrences of TEAEs are counted once per MedDRA preferred term. * Specific AE terms are provided in the Adverse Event section.
Time frame: Baseline (Day 0) up to follow-up visit (Day 562)
Mean Change From Baseline in the Monthly (28 Day) Average Number of Migraine Days
Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.
Time frame: Baseline, Month 12
Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity
Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.
Time frame: Baseline, Month 12
| Milestone | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group |
|---|---|---|
| Started | 25 | 25 |
| Completed | 23 | 21 |
| Not completed | 2 | 4 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
* TEAEs are defined as the AEs that started after trial investigational medicinal product (IMP) treatment. Multiple occurrences of TEAEs are counted once per MedDRA preferred term. * Specific AE terms are provided in the Adverse Event section.
| percentage of participants | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group |
|---|---|---|
| Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE) | 92.0 | 88.0 |
Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.
| days/month | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group |
|---|---|---|
| Mean Change From Baseline in the Monthly (28 Day) Average Number of Migraine Days | -5.9 ± 4.3 | -1.6 ± 5.7 |
Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.
| days/month | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group |
|---|---|---|
| Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity | -4.3 ± 4.1 | -2.1 ± 4.1 |
Collected over Baseline (Day 0) up to follow-up visit (Day 562). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TEV-48125 (225 mg/1 Month) Group | 0/25 (0%) | 0/25 (0%) | 20/25 (80%) |
| TEV-48125 (675 mg/3 Month) Group | 0/25 (0%) | 2/25 (8%) | 16/25 (64%) |
| Event | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group |
|---|---|---|
| Rhegmatogenous retinal detachmentEye disorders | 0/25 | 1/25 |
| Subarachnoid haemorrhageNervous system disorders | 0/25 | 1/25 |
| Event | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/25 | 14/25 |
| Injection site erythemaGeneral disorders | 7/25 | 5/25 |
| Injection site indurationGeneral disorders | 3/25 | 2/25 |
| Injection site painGeneral disorders | 1/25 | 3/25 |
| GastroenteritisInfections and infestations | 3/25 | 1/25 |
| Injection site pruritusGeneral disorders | 2/25 | 1/25 |
| InfluenzaInfections and infestations | 1/25 | 2/25 |
| Oral herpesInfections and infestations | 1/25 | 2/25 |
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 2/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/25 | 2/25 |
| Age, Categorical(Participants) | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 25 | 49 |
| >=65 years | 1 | 0 | 1 |
| Age, Continuous(years) | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group | Total |
|---|---|---|---|
| Mean | 46.8 ± 7.9 | 45.8 ± 7.0 | 46.3 ± 7.4 |
| Sex: Female, Male(Participants) | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group | Total |
|---|---|---|---|
| Female | 23 | 19 | 42 |
| Male | 2 | 6 | 8 |
| Race/Ethnicity, Customized(Participants) | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group | Total |
|---|---|---|---|
| Japanese | 25 | 25 | 50 |
| Region of Enrollment(Participants) | TEV-48125 (225 mg/1 Month) Group | TEV-48125 (675 mg/3 Month) Group | Total |
|---|---|---|---|
| Japan | 25 | 25 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2017 to primary completion in Jun 2020, 30 months.
Results were first posted in Jul 2021, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 30 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fremanezumab
Otsuka Pharmaceutical Co., Ltd. →